The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Positron emission tomography molecular imaging for drug development
Open accessAbstract
Human in vivo molecular imaging with positron emission tomography (PET) enables a new kind of ‘precision pharmacology’, able to address questions central to drug development. Biodistribution studies with drug molecules carrying positron‐emitting radioisotopes can test whether a new chemical entity reaches a target tissue compartment (such as the brain) in sufficient amounts to be pharmacologically active. Competition studies, using a radioligand that binds to the target of therapeutic interest with adequate specificity, enable direct assessment of the relationship between drug plasma concentration and target occupancy. Tailored radiotracers can be used to measure relative rates of biological processes, while radioligands specific for tissue markers expected to change with treatment can provide specific pharmacodynamic information. Integrated application of PET and magnetic resonance imaging (MRI) methods allows molecular interactions to be related directly to anatomical or physiological changes in a tissue. Applications of imaging in early drug development can suggest approaches to patient stratification for a personalized medicine able to deliver higher value from a drug after approval. Although imaging experimental medicine adds complexity to early drug development and costs per patient are high, appropriate use can increase returns on R and D investment by improving early decision making to reduce new drug attrition in later stages. We urge that the potential value of a translational molecular imaging strategy be considered routinely and at the earliest stages of new drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationKapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Synthesis of 11C, 18F, 15O, and 13N Radiolabels for Positron Emission Tomography
Miller, P. W., Long, N. J., Vilar, R., & Gee, A. D. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800222 · Cited by 894
Owen, D. R., Yeo, A. J., Gunn, R. N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D. J., Bennacef, I., Parker, C. A., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.147 · Cited by 779
Self-citationRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Wahl, R. L., Zasadny, K., Helvie, M., Hutchins, G. D., Weber, B., & Cody, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2101 · Cited by 605
Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Perez-Tomas, R. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777585077 · Cited by 509
PET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications
Pichler, B. J., Kolb, A., Nägele, T., & Schlemmer, H.-P. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.061853 · Cited by 418
Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands
Owen, D. R. J., Gunn, R. N., Rabiner, E. A., Bennacef, I., Fujita, M., Kreisl, W. C., Innis, R. B., Pike, V. W., Reynolds, R., Matthews, P. M., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079459 · Cited by 358
Self-citationBergstr�m, M., Grahn�n, A., & L�ngstr�m, B. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0643-x · Cited by 311
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.
Zhang, X., Xiong, Z., Wu, Y., Cai, W., Tseng, J. R., Gambhir, S. S., & Chen, X. S. (2006) · PubMed · Cited by 282
Van den Abbeele, A. D., & Badawi, R. D. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80604-9 · Cited by 257
Howes, O., Egerton, A., Allan, V., McGuire, P., Stokes, P., & Kapur, S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788957528 · Cited by 239
Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635
Pike, V. W., McCarron, J. A., Lammertsma, A. A., Osman, S., Hume, S. P., Sargent, P. A., Bench, C. J., Cliffe, I. A., Fletcher, A., & Grasby, P. M. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00079-9 · Cited by 226
Slifstein, M., & Laruelle, M. (2001) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(01)00214-1 · Cited by 204
Summerfield, S. G., Stevens, A. J., Cutler, L., del Carmen Osuna, M., Hammond, B., Tang, S.-P., Hersey, A., Spalding, D. J., & Jeffrey, P. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092916 · Cited by 175
Elsinga, P. H., Hendrikse, N. H., Bart, J., Vaalburg, W., & van Waarde, A. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384736 · Cited by 162
Rosso, L., Brock, C. S., Gallo, J. M., Saleem, A., Price, P. M., Turkheimer, F. E., & Aboagye, E. O. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2356 · Cited by 159
The potential of PET/MR for brain imaging
Heiss, W. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0962-3 · Cited by 140
Rabiner, E. A., Beaver, J. D., Makwana, A., Searle, G. E., Long, C., Nathan, P. J., Newbould, R. D., Howard, J., Miller, S. R., Bush, M., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.29 · Cited by 118
Self-citationFirst delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635
Pike, V. W., McCarron, J. A., Lammertsma, A. A., Hume, S. P., Poole, K., Grasby, P. M., Malizia, A. L., Cliffe, I. A., Fletcher, A., & Bench, C. J. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00438-q · Cited by 114
Predicting P-glycoprotein substrates by a quantitative structure–activity relationship model
Gombar, V. K., Polli, J. W., Humphreys, J. E., Wring, S. A., & Serabjit‐Singh, C. J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20035 · Cited by 112
Tzimopoulou, S., Cunningham, V. J., Nichols, T. E., Searle, G. E., Bird, N., Mistry, P. C., Dixon, I. J., Hallett, W. A., Whitcher, B. J., Brown, A. P., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100939 · Cited by 109
Self-citationSelective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse
Laporte, A., Lima, L., GOZLAN, H., & Hamon, M. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90812-5 · Cited by 108
Talbot, D. C., Ranson, M., Davies, J., Lahn, M., Callies, S., André, V., KADAM, S. K., Burgess, M., Slapak, C. A., Olsen, A. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1932 · Cited by 100
A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development
Guo, Q., Brady, M., & Gunn, R. N. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063800 · Cited by 75
Self-citationEvaluation of11C-GSK189254 as a Novel Radioligand for the H3Receptor in Humans Using PET
Ashworth, S., Rabiner, E. A., Gunn, R. N., Plisson, C., Wilson, A. A., Comley, R. A., Lai, R. Y. K., Gee, A. D., Laruelle, M. A., & Cunningham, V. J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.071753 · Cited by 74
Self-citationDegradative transport of cationic amphiphilic drugs across phospholipid bilayers
Baciu, M., Sébaï, S. C., Ces, O., Mulet, X., Clarke, J. A., Shearman, G. C., Law, R. V., Templer, R. H., Plisson, C., Parker, C. A., et al. (2006) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2006.1842 · Cited by 67
Abanades, S., van der Aart, J., Barletta, J. A., Marzano, C., Searle, G. E., Salinas, C. A., Ahmad, J. J., Reiley, R. R., Pampols-Maso, S., Zamuner, S., et al. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.175 · Cited by 61
Self-citationIn Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO
Girgis, R. R., Miyake, N., Xu, X., Easwaramoorthy, B., Castrillon, J., Gunn, R. N., Rabiner, E. A., Abi‐Dargham, A., & Slifstein, M. (2010) · Neuropsychopharmacology · doi:10.1016/j.neuroimage.2010.04.079 · Cited by 46
Self-citationAdaptive-Optimal Design in PET Occupancy Studies
Zamuner, S., Iorio, V., Nyberg, J., Gunn, R. N., Cunningham, V. J., Goméni, R., & Hooker, A. C. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.9 · Cited by 32
Self-citationTowards molecular imaging of multiple sclerosis
Owen, D. R., Piccini, P. P., & Matthews, P. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458510390070 · Cited by 13
Self-citationAdvances in the molecular imaging of multiple sclerosis
Matthews, P., & Comley, R. A. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.66 · Cited by 7
Self-citation
Cited by
Applications of Fluorine in Medicinal Chemistry
Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00258 · Cited by 3,618
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
18F-Labeling of Arenes and Heteroarenes for Applications in Positron Emission Tomography
Preshlock, S., Tredwell, M., & Gouverneur, V. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00493 · Cited by 679
Drug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673
Metadata
- Authors
- Matthews, P. M., Rabiner, E. A., Passchier, J., & Gunn, R. N.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2012-01-06
- Volume
- 73
- Issue
- 2
- Pages
- 175-186
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1546274595
- Cited by
- 320
- References
- 34
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.